Abstract: An object of the invention is to provide a peptide derived from a glioma-associated antigen being useful for the specific immunotherapy for glioma patients. The invention provides a KIF-derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of glioma.

Abstract: The object of the invention is to provide an EGFR-derived peptide useful for EGFR-based immunotherapy. The invention provides an EGFR-derived peptide capable of inducing both cellular and humoral immune responses and mutant peptide thereof and a polypeptide comprising said peptide, a nucleic acid molecule encoding the same, and a pharmaceutical composition comprising the same.

Abstract: Tumor antigen peptides that induce CTL from peripheral blood mononuclear cells of a patient with prostate cancer in an HLA-A2-restricted or an HLA-A24-restricted manner were identified based on the amino acid sequences of PSA, PSM, and PSCA, which are proteins known as markers of prostate cancer. Also disclosed is a peptide having a function as a tumor antigen that is recognized by HLA-A2-restricted CTL or HLA-A24-restricted CTL, an antibody against the peptide, a compound having interaction with the peptide, an agent for inducing CTL that includes the peptide, a pharmaceutical composition that includes one or more thereof, a method for identifying a compound that has interaction with the peptide, a method for inducing CTL using the peptide, a method for measuring the peptide and the antibody, as well as a reagent kit used for the identification method or the measurement method.

Abstract: Provided is a squamous cell carcinoma antigen derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of squamous cell carcinoma.

Abstract: A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided.

Abstract: A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided.

Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.

Abstract: The present invention relates to a tumor antigen peptide capable of inducing and/or activating HLA-A24-restricted and/or HLA-A2-restricted and tumor-specific cytotoxic T lymphocytes. The present invention also relates to a method of providing a polynucleotide encoding the peptide and a complementary strand thereto, a recombinant vector containing the polynucleotide, a transformant containing the recombinant vectors. The present invention also relates to a method for producing the peptide, an antibody against the peptide, a compound interacting with these entities and a method for screening for the compound, a pharmaceutical composition utilizing these entities, and a means for the diagnosis utilizing these entities.

Abstract: The present invention provides a method for treating a cancer patient which comprises administering a therapeutically effective amount of a cancer antigen peptide to the patient in need thereof, wherein the method comprises the steps of 1) providing a set of cancer antigen peptides comprising two or more cancer antigen peptides, 2) determining whether or not the patient has a peptide-specific cytotoxic T lymphocyte precursor which is specific to each peptide in the set of cancer antigen peptides, 3) removing the cancer antigen peptide to which the patient does not have the peptide-specific cytotoxic T lymphocyte precursor from the set of cancer antigen peptides to provide an administration set of cancer antigen peptides, 4) administering the administration set of cancer antigen peptides to the patient.

Abstract: The correlation of clinical benefits and immune responses to peptides in cancer patients who were vaccinated with CTL-directed peptides is shown. The invention relates to a process for determining prognosis in a cancer patient vaccinated with a cancer antigen peptide-associated agent, which comprises measuring a level of an antibody specific to the cancer antigen peptide, and assessing whether the level is significantly increased as compared to the level at pre-vaccination.

Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.

Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.

Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.

Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.

Abstract: The object of the invention is to provide an EGFR-derived peptide useful for EGFR-based immunotherapy. The invention provides an EGFR-derived peptide capable of inducing both cellular and humoral immune responses and mutant peptide thereof and a polypeptide comprising said peptide, a nucleic acid molecule encoding the same, and a pharmaceutical composition comprising the same.

Abstract: Tumor antigen peptides derived from cyclophilins or derivatives thereof having the functionally equivalent properties; medicaments, prophylactics, or diagnostics for tumors comprising as an active ingredient such tumor antigen peptides or derivatives thereof, cyclophilins or partial polypeptides thereof, or genes encoding said cyclophilins or partial polypeptides thereof; in vitro use of the above substances for treatment of tumors; and antibodies against the above tumor antigen peptides derived from cyclophilins or derivatives thereof are provided.

Abstract: Disclosed is a peptide derived from hepatitis C virus comprising an HLA-binding motif in its sequence and being recognized by an antibody detected in a patient with hepatitis C virus (HCV) infection. The peptide of the present invention is useful in diagnosing hepatitis C virus, treating hepatitis C, and predicting the prognosis of hepatitis C.

Abstract: Tumor antigen peptides that induce CTL from peripheral blood mononuclear cells of a patient with prostate cancer in an HLA-A2-restricted or an HLA-A24-restricted manner were identified based on the amino acid sequences of PSA, PSM, and PSCA, which are proteins known as markers of prostate cancer. Also disclosed is a peptide having a function as a tumor antigen that is recognized by HLA-A2-restricted CTL or HLA-A24-restricted CTL, an antibody against the peptide, a compound having interaction with the peptide, an agent for inducing CTL that includes the peptide, a pharmaceutical composition that includes one or more thereof, a method for identifying a compound that has interaction with the peptide, a method for inducing CTL using the peptide, a method for measuring the peptide and the antibody, as well as a reagent kit used for the identification method or the measurement method.

Abstract: A cancer antigen peptide which is a partial peptide derived from parathyroid hormone-related protein, and which is capable of binding to an HLA-A24 or HLA-A2 antigen and being recognized by cytotoxic T lymphocytes, or a derivative thereof having the functionally equivalent properties, can be useful for the treatment and prevention of prostate cancer.

Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.